ORIGINAL RESEARCH article
Front. Oncol.
Sec. Thoracic Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1645692
This article is part of the Research TopicCommunity Series in Unveiling the Next Generation of Cancer Immunity & Immunotherapy in Lung Cancer: Volume IIView all articles
Effectiveness and Safety of Serplulimab Plus Platinum-Based Chemotherapy in First-Line Treatment of Extensive-Stage Small Cell Lung Cancer Liver Metastases: A Retrospective Cohort Study
Provisionally accepted
Wenzhong Su*
Yifei Chen- Shanxi Cancer Hospital ,Urology Surgery, Tai Yuan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background The role of immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) liver metastases remains controversial. This study aimed to evaluate the effectiveness and safety of serplulimab combined with platinum-based chemotherapy as a first-line treatment for these patients. Methods This retrospective cohort study reviewed patients with ES-SCLC liver metastases who received serplulimab plus platinum-based chemotherapy as a first-line treatment. Outcomes included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. The associations between prognosis and the depth of remission of primary lung lesions and liver metastases were analysed. Results Among the 30 ES-SCLC patients (median age, 67 years), the ORR was 63.3% (95% CI, 43.9-80.1), and the DCR was 83.3% (95% CI, 65.3-94.4). The median PFS was 5.9 months (95% CI, 4.3-8.1), and the median OS was 9.1 months (95% CI, 6.1-16.2). Patients with a depth of remission of primary lung lesions ≥30% (n=14) had a significantly longer median PFS (8.1 months [95% CI, 6.4-NE] vs. 3.9 months [95% CI, 3.2-6.3], HR:0.28, 95%CI: 0.12-0.65) and OS (16.2 months [95% CI, 9.1-NE] vs. 5.5 months [95% CI, 3.7-13.6], HR: 0.31, 95%CI: 0.12-0.81) than those with a depth of remission <30% (n=16). Patients with a depth of remission of liver metastases ≥30% (n=9) had a significantly extended median OS than those with a depth of remission <30% (n=20) (16.2 months [95% CI, 10.4-NE] vs. 6.3 months [95% CI, 4.4-13.6], HR: 0.21, 95%CI: 0.06-0.73). The most common adverse events were nausea (40.0%), leukopenia (26.7%), and neutropenia (26.7%). Conclusion This real-world study demonstrates promising effectiveness and a manageable safety profile for the combination of serplulimab with platinum-based chemotherapy in treating ES-SCLC liver metastases, which suggests that this treatment regimen may provide an attractive option for the first-line management of ES-SCLC liver metastases.
Keywords: Small Cell Lung Carcinoma, Liver Neoplasms, Immunotherapy, serplulimab, treatment outcome
Received: 23 Jun 2025; Accepted: 10 Sep 2025.
Copyright: © 2025 Su and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wenzhong Su, Shanxi Cancer Hospital ,Urology Surgery, Tai Yuan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.